Last --
Change Today 0.00 / 0.00%
Volume 0.0
FSXMF On Other Exchanges
Symbol
Exchange
Continuous
OTC US
Berlin
All times are local (Market data is delayed by at least 15 minutes).

faes farma sa (FSXMF) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
235.0M
EX-Date
06/6/14
P/E TM
--
Dividend
$0.08
Dividend Yield
--
Current Stock Chart for FAES FARMA SA (FSXMF)

Related News

No related news articles were found.

faes farma sa (FSXMF) Related Businessweek News

No Related Businessweek News Found

faes farma sa (FSXMF) Details

Faes Farma, S.A. is engaged in the research, development, manufacture, marketing, and sale of pharmaceutical products and raw materials in Spain, Portugal, and internationally. The company offers prescription, OTC, and skin-care treatment products. Its products include Bilastine, a non-sedating antihistamine for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria in adults and children; F-97013-GD, an antipsychotic product, which is in pre-clinical phases; F-98214-TA, an antidepressant that is in pre-clinical phases; and Serotonin reuptake inhibitors. The company also manufactures raw materials, such as diosmin, hidrosmin, magnesium pidolate, and arginine aspartate, as well as granulated diosmin, glutodine, trimethropim, and pyrrolidone carboxylate. Faes Farma, S.A. was founded in 1933 and is headquartered in Bilbao, Spain.

Founded in 1933

faes farma sa (FSXMF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

faes farma sa (FSXMF) Key Developments

Faes Farma Reports Consolidated Earnings Results for the First Six Months of 2014

Faes Farma reported consolidated earnings results for the first six months of 2014. For the period, the company reported net profit of EUR 14 million for the first half of 2014, up 10.6% on the year. Revenue stood at EUR 99 million, compared with EUR 96.4 million a year earlier. Earnings before interest, tax, depreciation and amortisation went up 8.8% to EUR 21.6 million. Earnings before interest and tax jumped by 20% to EUR 16.9 million. Pre-tax profits stood at EUR 21.6 million (USD 28 million), 8.8% more than in the first half of 2013.

Faes Farma, S.A., Annual General Meeting, Jun 25, 2014

Faes Farma, S.A., Annual General Meeting, Jun 25, 2014. Location: Palacio Euskalduna. Avda. Abandoibarra.

Tribute Pharmaceuticals Canada Inc. and Faes Farma, S.A. Announce Exclusive License Agreement in Canada for Bilastine

Tribute Pharmaceuticals Canada Inc. and Faes Farma, S.A. announced the signing of an exclusive license agreement that grants Tribute the exclusive right to sell Faes's Bilastine product for the treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria (hives) in Canada, following receipt of regulatory approval from Health Canada for such product. The exclusive license is inclusive of prescription and nonprescription rights for Bilastine, as well as adult and paediatric presentations in Canada. Allergic rhinitis and urticaria are both allergic disorders that can adversely affect quality of life to the extent that work or school productivity may be impaired.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FSXMF:US $0.00 USD 0.00

FSXMF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Recordati SpA €13.80 EUR -0.05
Salix Pharmaceuticals Ltd $143.85 USD -0.65
Shire PLC 4,163 GBp -1.00
Procter & Gamble Co/The $87.27 USD +0.33
View Industry Companies
 

Industry Analysis

FSXMF

Industry Average

Valuation FSXMF Industry Range
Price/Earnings 18.0x
Price/Sales 2.2x
Price/Book -- Not Meaningful
Price/Cash Flow 14.2x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FAES FARMA SA, please visit www.faes.es. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.